314 related articles for article (PubMed ID: 18752081)
1. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis.
Zhu X; Stergiopoulos K; Wu S
Acta Oncol; 2009; 48(1):9-17. PubMed ID: 18752081
[TBL] [Abstract][Full Text] [Related]
2. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis.
Chu D; Lacouture ME; Weiner E; Wu S
Clin Genitourin Cancer; 2009 Jan; 7(1):11-9. PubMed ID: 19213662
[TBL] [Abstract][Full Text] [Related]
3. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
4. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
5. Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib.
George S; Reichardt P; Lechner T; Li S; Cohen DP; Demetri GD
Ann Oncol; 2012 Dec; 23(12):3180-3187. PubMed ID: 22858558
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.
Richards CJ; Je Y; Schutz FA; Heng DY; Dallabrida SM; Moslehi JJ; Choueiri TK
J Clin Oncol; 2011 Sep; 29(25):3450-6. PubMed ID: 21810682
[TBL] [Abstract][Full Text] [Related]
7. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib.
Mickisch G; Gore M; Escudier B; Procopio G; Walzer S; Nuijten M
Br J Cancer; 2010 Jan; 102(1):80-6. PubMed ID: 19920817
[TBL] [Abstract][Full Text] [Related]
8. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
9. Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Santoni M; Conti A; Massari F; Arnaldi G; Iacovelli R; Rizzo M; De Giorgi U; Trementino L; Procopio G; Tortora G; Cascinu S
Int J Cancer; 2015 Jan; 136(1):1-10. PubMed ID: 24415642
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib.
Heng DY; Kollmannsberger C
Recent Results Cancer Res; 2010; 184():71-82. PubMed ID: 20072832
[TBL] [Abstract][Full Text] [Related]
11. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Choueiri TK; Schutz FA; Je Y; Rosenberg JE; Bellmunt J
J Clin Oncol; 2010 May; 28(13):2280-5. PubMed ID: 20351323
[TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
[TBL] [Abstract][Full Text] [Related]
13. Risk of cardiovascular toxicities in patients with solid tumors treated with sunitinib, axitinib, cediranib or regorafenib: an updated systematic review and comparative meta-analysis.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2014 Dec; 92(3):194-207. PubMed ID: 25028151
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and toxicity of sunitinib for non clear cell renal cell carcinoma (RCC): a systematic review of the literature.
Abdel-Rahman O; Fouad M
Crit Rev Oncol Hematol; 2015 May; 94(2):238-50. PubMed ID: 25638704
[TBL] [Abstract][Full Text] [Related]
15. Sunitinib malate for the treatment of renal cell carcinoma.
Wood L
Expert Opin Pharmacother; 2012 Jun; 13(9):1323-36. PubMed ID: 22607009
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib outscores sunitinib on tolerability.
Cancer Discov; 2014 Jan; 4(1):OF8. PubMed ID: 24402960
[TBL] [Abstract][Full Text] [Related]
17. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
[TBL] [Abstract][Full Text] [Related]
18. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Wu S; Chen JJ; Kudelka A; Lu J; Zhu X
Lancet Oncol; 2008 Feb; 9(2):117-23. PubMed ID: 18221915
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.
Michels J; Lassau N; Gross-Goupil M; Massard C; Mejean A; Escudier B
Invest New Drugs; 2010 Oct; 28(5):690-3. PubMed ID: 19547920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]